ViewRay has nabbed up to $50 million in debt financing from healthcare investor CRG after canceling a proposed $52 million IPO in April. The cash will go to help commercialize its MRI-guided radiation therapy as well as to refinance existing debt.
In 2012, the Morris Animal Foundation launched its Golden Retriever Lifetime Study, which is expected to last 15 years and is aimed at identifying important risk factors for cancer and other diseases. Now the foundation has released its first paper from the study, which was published in a special cancer-themed issue of the journal Philosophical Transactions B.
Women generally fare better than men after picking up cancer, but research presented at the Cancer Outcomes Conference in Belfast, Northern Ireland, found that the reverse is true among sufferers of bladder cancer. The information has informed a U.K. public advertising campaign to raise awareness of the disease.
Newly public genetic information company Invitae has dropped prices for its genetic tests, just as the NIH says it will launch a study of the efficacy of cancer drugs by genetic mutation. Both are a testament to the rapidly evolving role of genetic information in patient treatment.
A Singapore-led clinical group has published a study of a novel approach to investigating how genes affect options to treat liver cancer, highlighting the city-state's growing role in oncology research.
Royal Philips and the Massachusetts Institute of Technology (MIT) have partnered in a 5-year research alliance with a $25 million budget to develop novel product solutions in healthcare and lighting.
Express Scripts has been warning about a crackdown on cancer drug spending. Now, it's talking about how.
Roche's Ventana Medical Systems announced a companion diagnostic agreement centered around Astellas Pharma's cancer fighting ASP5878.
Roche snatched up genomics research outfit CAPP Medical to get its hands on the company's cancer detection platform, continuing its M&A streak and strengthening its foothold in cancer R&D.
Australia's reimbursement agency has lagged developed country counterparts in paying for newly approved new cancer therapies, highlighting problems at the tail end of a system that patients and industry complain is broken.